FAST NEWS: Luye Pharma’s Schizophrenia Drug Wins FDA Approval
The latest: Drug maker Luye Pharma Group Ltd. announced Sunday that its drug Rykindo has been approved by the U.S. Food and Drug Administration (FDA) as a treatment for schizophrenia…
MingMed Biotech Joins Queue of Revenue-less Drug Startups Seeking IPO Cash
It has seven drugs under development but none on the market yet. But one thing MingMed Biotech has plenty of is losses Key Takeaways: With no drug revenues and growing…
FAST NEWS: Legend Biotech Plans $250 Million ADS Public Offering
The latest: Genscript Biotech Corp. (1548.HK) announced its New York-listed subsidiary, Legend Biotech Corp. (LEGN.US), plans to conduct a public offering of $250 million worth of American Depository Shares (ADS).…
RLX Burns Down, But Not Out, With New Licensing Announcement
China’s tobacco regulator allows the nation’s top vaping brand to manufacture at levels about 30% lower than its sales for last year Key Takeaways: RLX has received a new manufacturing…
FAST NEWS: Legend Biotech Pares Losses on Milestone Revenue
The latest: Legend Biotech Corp. (LEGN.US), a cell therapy subsidiary of Genscript Biotech Corp. (1548.HK), reported a loss of $41.09 million in the first quarter, half the $80.9 million loss from the same…
Amid Slowing Sales at Home, Innovent Biologics Stumbles Overseas
Cancer drug maker ended a tie-up to bring one of its drugs to North America last week, less than two months after its best-selling product was rejected by the FDA…
FAST NEWS: HutchMed Shares Plunge on U.S. Cancer Drug Rejection
The latest: HutchMed (China) Ltd. (HCM.US; 0013.HK) announced late Monday that its Surufatinib drug for the treatment of advanced neuroendocrine tumors was denied approval by the U.S. Food and Drug…
